STELLAR-303
Exelixis’ Zanzalintinib Achieves Key Survival Goal in Pivotal Colorectal Cancer Study
Exelixis; zanzalintinib; colorectal cancer; pivotal trial; overall survival; atezolizumab; checkpoint inhibitor; Stivarga; STELLAR-303; clinical trial
Exelixis’ Phase 3 Colorectal Cancer Data Sends Stock Higher
Exelixis; zanzalintinib; colorectal cancer; Phase 3 trial; STELLAR-303; Tecentriq; Regorafenib; clinical trial results; stock surge